Company Encyclopedia
View More
name
DUALITYBIO-B
09606.HK
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd. to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC.
1.262 T
09606.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Large Transactions" DUALITYBIO-B saw a cross trade of approximately 70,000 shares, involving a capital of 21.19 million yuan

    According to the Economic News Agency report on the 5th, DUALITYBIO-B recorded a cross trade of 71,000 shares at 2:19 PM, with each share priced at HKD 298.5, up 0.4% from the previous closing price, involving a total of HKD 21.19 million. DUALITYBIO-B is currently up 0.6%, priced at HKD 299.2; with a trading volume of 1.1013 million shares and a transaction amount of HKD 321 million, the active buy-sell ratio is 57:43, with a net active buying of HKD 37.43 million. (rw)

    etnet·
    HK
    09606
    +1.30%
    etnet·
    HK
    09606
    +1.30%

    Understanding the Market | DUALITYBIO-B rose over 13% during the session, recently announced plans to list on the Sci-Tech Innovation Board, with total BD transactions exceeding 6 billion USD

    DUALITYBIO-B rose over 13% during intraday trading, and as of the time of writing, it is up 11.1%, priced at HKD 314.4, with a trading volume of HKD 573 million. In terms of news, DUALITYBIO previously announced that the company's board of directors has resolved to plan for a listing on the STAR Market, which is subject to market conditions and requires further approval from the board of directors, the shareholders' meeting, and regulatory agency permission. It is reported that on April 15 of this year, DUALITYBIO was officially listed on the main board of the Hong Kong Stock Exchange, raising over HKD 1.5 billion in its IPO, making it one of the largest IPOs in the Hong Kong stock market's 18A sector in the past four years. Guotai Junan Securities released a research report stating that the rapid pace of innovation has stimulated large-scale transactions in the ADC technology field, and the company has reached multiple external licensing and cooperation agreements with several industry-leading enterprises globally, including BioNTech, BeiGene, Adcendo, GSK, and Avenzo. The confirmed BD revenue for the first half of 2023/2024/2025 is expected to be RMB 1.781 billion / 1.937 billion / 1.227 billion, with a total transaction value exceeding USD 6 billion

    Zhitong·
    HK
    09606
    +1.30%
    Zhitong·
    HK
    09606
    +1.30%

    Zhitong Hong Kong Stock Connect Proportion Anomaly Statistics | October 24

    As of October 23, 2025, the Hong Kong Stock Connect shareholding ratios of DL HOLDINGS GP, GX HSCEI Technology, and YOFC increased by 4.49%, 2.10%, and 1.63%, respectively. Meanwhile, the shareholding ratios of HSCEI ETF, Tracker Fund of Hong Kong, and Dongfang Electric decreased by 2.09%, 0.96%, and 0.89%, respectively. In the last 5 trading days, the shareholding ratios of DUALITYBIO-B, GX HSCEI Technology, and Shandong Molong increased by 10.58%, 10.22%, and 5.17%, respectively

    Zhitong·
    HK
    02828
    -1.84%
    SH
    601869
    -6.15%
    HK
    06869
    -9.22%
    Zhitong·
    HK
    02828
    -1.84%
    SH
    601869
    -6.15%
    HK
    06869
    -9.22%

    Zhitong Hong Kong Stock Connect Proportion Change Statistics | October 22

    According to data from October 21, 2025, the shareholding ratios of Shandong Molong, Hang Seng China Enterprises, and DualityBio-B in the Hong Kong Stock Connect have increased by 5.60%, 2.74%, and 2.24%, respectively. In contrast, the shareholding ratios of Goldwind Technology, Yangtze Optical Fibre and Cable, and Shanghai Electric have decreased by -1.90%, -1.74%, and -1.15%, respectively. In the last 5 trading days, the shareholding ratio of DualityBio-B increased by 8.96%, while Ocean Park Hong Kong decreased by 5.61%

    Zhitong·
    SH
    601727
    -3.01%
    HK
    02727
    -4.12%
    HK
    09606
    +1.30%
    Zhitong·
    SH
    601727
    -3.01%
    HK
    02727
    -4.12%
    HK
    09606
    +1.30%

    "First H then A" second deal of the year: After raising nearly 1.8 billion in Hong Kong stocks, DUALITYBIO is preparing for the Sci-Tech Innovation Board

    As A-share companies rush to the Hong Kong Stock Exchange, reverse operations are quietly rising. Recently, DUALITYBIO announced plans to go public on the Sci-Tech Innovation Board

    Wallstreetcn·
    HK
    09606
    +1.30%
    Wallstreetcn·
    HK
    09606
    +1.30%
    Posts
    View More

    $LEADS BIOLABS-B(09887.HK) Let's go all in $DUALITYBIO-B(09606.HK) hoping to replicate the trend.

    • 0
    © 2025 Longbridge｜Disclaimer